Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond

Epidermal growth factor receptor (EGFR) tyrosine inhibitors were first approved for the treatment of non-small cell lung cancer (NSCLC) in 2003 in the US. Activating EGFR mutations were subsequently discovered in 2004, and heralded the era of molecular targeted therapy in NSCLC. The discovery of ana...

Descripción completa

Detalles Bibliográficos
Autor principal: Ou, Sai-Hong Ignatius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232174/
https://www.ncbi.nlm.nih.gov/pubmed/22162641
http://dx.doi.org/10.2147/DDDT.S19045

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232174/
https://www.ncbi.nlm.nih.gov/pubmed/22162641
http://dx.doi.org/10.2147/DDDT.S19045

Ejemplares similares